RHB-102 (BEKINDA®) is a patent-protected, proprietary, once-daily, bimodal extended-release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist.
RHB-102 is in development for several gastrointestinal indications:
Our Collaborations for RHB-102:
On February 25, 2025, we entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals for RHB-102 for gastroenteritis & gastritis, IBS-D and oncology support. Learn more.
* Bekinda® is the proposed tradename for RHB-102, which is subject to review by the FDA at the time of NDA filing